Voriconazole : a Review of Its Use in the Management of Invasive Fungal Infections

Overview

Journal Drugs

Specialty Pharmacology

Date 2007 Feb 8

PMID 17284090

Citations 59

Authors

Lesley J Scott

Dene Simpson

Affiliations

Soon will be listed here.

Abstract

Voriconazole (VFEND), a synthetic second-generation, broad-spectrum triazole derivative of fluconazole, inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth. In the US, intravenous and/or oral voriconazole is recommended in adults for the treatment of invasive aspergillosis, candidaemia in non-neutropenic patients, disseminated infections caused by Candida spp., oesophageal candidiasis, and in patients with scedosporiosis and fusariosis who are refractory to or intolerant of other antifungal therapy. In Europe, intravenous and/or oral voriconazole is recommended in adults and paediatric patients of at least 2 years of age for the treatment of invasive aspergillosis, candidaemia in non-neutropenic patients, fluconazole-resistant serious invasive Candida spp. infections, scedosporiosis and fusariosis. In large randomised trials, voriconazole was an effective and generally well tolerated primary treatment for candidiasis and invasive aspergillosis in adults and adolescents. More limited data also support the use of voriconazole for the treatment of invasive fungal infections in children, in those with rare fungal infections, such as Fusarium spp. or Scedosporium spp., and in those refractory to or intolerant of other standard antifungal therapies. The availability of both parenteral and oral formulations and the almost complete absorption of the drug after oral administration provide for ease of use and potential cost savings, and ensure that therapeutic plasma concentrations are maintained when switching from intravenous to oral therapy. On the other hand, the numerous drug interactions associated with voriconazole may limit its usefulness in some patients. Further clinical experience will help to more fully determine the position of voriconazole in relation to other licensed antifungal agents. In the meantime, voriconazole is a valuable emerging option for the treatment of invasive aspergillosis and rare fungal infections, including Fusarium spp. and Scedosporium spp. infections, and provides an alternative option for the treatment of candidiasis, particularly where the causative organism is inherently resistant to other licensed antifungal agents.

Citing Articles

Antifungal activity and biocompatibility assessment with molecular docking and dynamic simulations of new pyrazole derivatives.

Abd-Elhalim B, El-Bana G, El-Sayed A, Abdel-Ghani G BMC Biotechnol. 2025; 25(1):15.

PMID: 39915777 PMC: 11800497. DOI: 10.1186/s12896-025-00948-8.

Disseminated Gastrointestinal Basidiobolomycosis: A Case Report with Review of Diagnostic Clues.

Soleimani N, Anbardar M, Nikoupour H, Derakhshan F, Shafiekhani M, Mohammadzadeh S Case Rep Med. 2024; 2024:5741625.

PMID: 39233673 PMC: 11374415. DOI: 10.1155/2024/5741625.

Extracellular phospholipase production by Malassezia pachydermatis strains and its inhibition by selected antimycotics and plant essential oil components.

conkova E, Vaczi P, Malinovska Z Vet Res Commun. 2024; 48(5):3271-3282.

PMID: 38922388 PMC: 11442620. DOI: 10.1007/s11259-024-10446-5.

Efficacy of the Combined Intrastromal Injection of Voriconazole and Amphotericin B in Recalcitrant Fungal Keratitis.

Moramarco A, Grendele A, Iannetta D, Ottoboni S, Gregori G, di Geronimo N Microorganisms. 2024; 12(5).

PMID: 38792749 PMC: 11124487. DOI: 10.3390/microorganisms12050922.

Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.

Axler E, Lipner S Infect Drug Resist. 2024; 17:819-843.

PMID: 38463386 PMC: 10922011. DOI: 10.2147/IDR.S431526.

References

Lionakis M, Kontoyiannis D . Sinus zygomycosis in a patient receiving voriconazole prophylaxis. Br J Haematol. 2005; 129(1):2. DOI: 10.1111/j.1365-2141.2005.05384.x. View

Pfaller M, Diekema D, Boyken L, Messer S, Tendolkar S, Hollis R . Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol. 2003; 41(5):1875-80. PMC: 154736. DOI: 10.1128/JCM.41.5.1875-1880.2003. View

Pfaller M, Diekema D, Rinaldi M, BARNES R, Hu B, Veselov A . Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol. 2005; 43(12):5848-59. PMC: 1317207. DOI: 10.1128/JCM.43.12.5848-5859.2005. View

Pfaller M, Boyken L, Messer S, Tendolkar S, Hollis R, Diekema D . Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol. 2005; 43(10):5208-13. PMC: 1248491. DOI: 10.1128/JCM.43.10.5208-5213.2005. View

Vincent A, Cabrero J, Greene J, Sandin R . Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control. 2003; 10(5):414-9. DOI: 10.1177/107327480301000511. View

Purkins L, Wood N, Greenhalgh K, Allen M, Oliver S . Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003; 56 Suppl 1:10-6. PMC: 1884314. DOI: 10.1046/j.1365-2125.2003.01993.x. View

Marty F, Cosimi L, Baden L . Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004; 350(9):950-2. DOI: 10.1056/NEJM200402263500923. View

Vigouroux S, Morin O, Moreau P, Mechinaud F, Morineau N, Mahe B . Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis. 2005; 40(4):e35-7. DOI: 10.1086/427752. View

Denning D, Kibbler C, Barnes R . British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis. 2003; 3(4):230-40. DOI: 10.1016/s1473-3099(03)00580-2. View

10.

Barchiesi F, Spreghini E, Maracci M, Fothergill A, Baldassarri I, Rinaldi M . In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother. 2004; 48(9):3317-22. PMC: 514763. DOI: 10.1128/AAC.48.9.3317-3322.2004. View

11.

Sanati H, Belanger P, Fratti R, Ghannoum M . A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother. 1997; 41(11):2492-6. PMC: 164150. DOI: 10.1128/AAC.41.11.2492. View

12.

Huang D, Wu J, Lahart C . Toxic epidermal necrolysis as a complication of treatment with voriconazole. South Med J. 2004; 97(11):1116-7. DOI: 10.1097/01.SMJ.0000144618.80128.F9. View

13.

Ritz N, Ammann R, Casaulta Aebischer C, Gugger M, Jaton K, Schmid R . Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr. 2005; 164(4):231-5. DOI: 10.1007/s00431-004-1606-7. View

14.

Fortun J, Martin-Davila P, Sanchez M, Pintado V, Alvarez M, Sanchez-Sousa A . Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis. 2003; 22(7):408-13. DOI: 10.1007/s10096-003-0960-0. View

15.

Muijsers R, Goa K, Scott L . Voriconazole: in the treatment of invasive aspergillosis. Drugs. 2002; 62(18):2655-64; discussion 2665-6. DOI: 10.2165/00003495-200262180-00010. View

16.

Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, DuPont B . A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001; 33(9):1447-54. DOI: 10.1086/322653. View

17.

Ullmann A . Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin. 2003; 19(4):263-71. DOI: 10.1185/030079903125001884. View

18.

Gonzalez G, Fothergill A, Sutton D, Rinaldi M, Loebenberg D . In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol. 2005; 43(3):281-4. DOI: 10.1080/13693780500088416. View

19.

Patterson T . Advances and challenges in management of invasive mycoses. Lancet. 2005; 366(9490):1013-25. DOI: 10.1016/S0140-6736(05)67381-3. View

20.

Scherpbier H, Hilhorst M, Kuijpers T . Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis. 2003; 37(6):828-30. DOI: 10.1086/376985. View